U.S. stock market update: ALX Oncology up 11.61%

U.S. Stock Market Midday Update

Stocks with High Trading Volume in the Industry

PepGen rose 126.32%, with increased trading volume. Based on recent important news:

1. On September 25, PepGen announced that its experimental drug PGN-EDODM1 showed the ability to improve the cellular processing of genetic instructions in patients with muscle diseases during early trials, leading to a 130% increase in stock price. The drug aims to treat muscle atrophy diseases, and PepGen believes that correcting erroneous RNA splicing can help reverse symptoms. Source: Company announcement.

2. On September 25, PepGen announced a public offering priced at $100 million, issuing 31,250,000 shares at a price of $3.20 per share. This move aims to support its research and clinical trials, driving the stock price up. Source: Company announcement.

3. On September 25, Guggenheim reiterated its buy rating on PepGen and maintained a target price of $6, further boosting the stock price. Source: Analyst report. Market volatility is significant, and industry trends should be monitored.

uniQure rose 8.47%, with a trading volume of $550 million. Based on recent important news:

1. On September 25, uniQure announced that its AMT-130 gene therapy showed significant disease progression slowing effects in early to mid-stage trials for Huntington's disease, causing the stock price to soar by about 248%. Data indicates that the therapy has potential breakthrough capabilities, boosting market optimism about the company's prospects. Source: Company announcement.

2. On September 25, uniQure launched a $200 million public offering, including common stock and pre-funded warrants, to support the potential commercialization of AMT-130 in the U.S. This move enhances the company's financial flexibility. Source: Company announcement.

3. On September 25, Stifel and Chardan Capital raised their target prices for uniQure to $65 and $76, respectively, reflecting analysts' confidence in the company's future growth. Source: Analyst report. The outlook for the gene therapy industry is optimistic, with significant capital inflow.

AbbVie fell 0.59%, with a trading volume of $411 million. Based on recent key news:

1. On September 25, a U.S. federal judge dismissed AbbVie and Novartis's attempt to challenge Maine's law regulating the use of contract pharmacies under the federal 340B drug discount program. This ruling may negatively impact AbbVie's market performance.

2. On September 23, AbbVie announced that its ibrutinib injection has filed for new indications in China, which may drive its market expansion in China.

3. On September 24, AbbVie announced the acquisition of Capstan, promoting development in the immunology field, which may have a positive impact on its long-term growth. Industry trends are stable, and capital flows are active Stocks Ranked Among the Top by Market Capitalization in the Industry

Amgen fell 2.45%, with a market capitalization of $146.6 billion. Based on recent important news:

1. On September 24, Citigroup raised Amgen's target price from $310 to $315, maintaining a "Hold" rating. This move indicates an increase in market confidence in Amgen, but failed to significantly boost the stock price.

2. On September 23, market analysis suggested that despite Amgen's non-GAAP earnings per share guidance being raised, the stock price remains under pressure due to political pressures facing the pharmaceutical industry.

3. On September 23, market analysts generally maintained a "Hold" rating on Amgen, believing that five other stocks offer greater investment value, which has had a certain negative impact on Amgen's market performance. The pharmaceutical industry is facing political pressure, leading to stock price volatility